ASCENDIS PHARMA A/S's ticker is ASND and the CUSIP is 04351P101. A total of 33 filers reported holding ASCENDIS PHARMA A/S in Q2 2015. The put-call ratio across all filers is - and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,580,758 | +163.4% | 112,994 | +151.1% | 0.07% | +140.0% |
| Q2 2023 | $4,016,250 | -16.8% | 45,000 | 0.0% | 0.03% | -28.6% |
| Q1 2023 | $4,824,900 | +7.2% | 45,000 | +15.1% | 0.04% | -27.6% |
| Q2 2019 | $4,502,000 | -31.5% | 39,101 | -30.0% | 0.06% | -33.3% |
| Q1 2019 | $6,577,000 | +930.9% | 55,878 | +520.9% | 0.09% | +1142.9% |
| Q3 2018 | $638,000 | -74.2% | 9,000 | -75.8% | 0.01% | -68.2% |
| Q2 2018 | $2,474,000 | +41.7% | 37,190 | +39.3% | 0.02% | +57.1% |
| Q1 2018 | $1,746,000 | -49.6% | 26,700 | -69.1% | 0.01% | -50.0% |
| Q4 2017 | $3,465,000 | -13.1% | 86,500 | -21.4% | 0.03% | -6.7% |
| Q3 2017 | $3,988,000 | +236.0% | 110,000 | +64.0% | 0.03% | +114.3% |
| Q3 2015 | $1,187,000 | -44.9% | 67,079 | -45.0% | 0.01% | +16.7% |
| Q2 2015 | $2,154,000 | +24.2% | 121,880 | +21.9% | 0.01% | -50.0% |
| Q1 2015 | $1,734,000 | – | 99,955 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Vivo Capital, LLC | 1,797,745 | $265,886,000 | 19.06% |
| RA Capital Management | 4,914,955 | $726,922,000 | 14.16% |
| Sofinnova Investments, Inc. | 1,109,874 | $164,150,000 | 10.35% |
| Eventide Asset Management | 1,709,848 | $252,887,000 | 5.50% |
| Asymmetry Capital Management, L.P. | 47,599 | $7,040,000 | 5.39% |
| BERYLSON CAPITAL PARTNERS, LLC | 58,200 | $8,608,000 | 5.30% |
| Avoro Capital Advisors LLC | 1,750,000 | $258,825,000 | 5.12% |
| Eversept Partners, LP | 220,344 | $32,588,878 | 4.47% |
| Spyglass Capital Management LLC | 452,104 | $66,866,000 | 4.14% |
| Orbimed Advisors | 1,562,986 | $231,166,000 | 3.25% |